Mesothelin – A Potential New Target For Ovarian Cancer ImmunoTherapy

Researchers have generated altered immune cells that are able to shrink, and in some cases eradicate, large tumors in mice. The immune cells target mesothelin, a protein that is highly expressed, or translated in large amounts from the mesothelin gene, on the surface of several types of cancer cells. The approach, developed by researchers at the National Cancer Institute (NCI), part of the National Institutes of Health, and at the University of Pennsylvania School of Medicine, shows promise in the development of immunotherapies for certain tumors. The study appeared online the week of Feb. 9, 2009, in the Proceedings of the National Academy of Sciences. In a more recent study, appearing online May 5, 2009, in Molecular Cancer Therapeutics, NCI researchers developed a human antibody against mesothelin that shows potential, in laboratory experiments, for cancer treatment and diagnosis.

Continue reading